TAAs refer to molecules of 10-1000-fold increase in tumor cells compared to those in normal cells, such as HER2, p53, and MART-1, while TSAs are neoantigens such as NY-ESO-1 and CEA that are absent or restrictively expressed in normal cells, thus being preferred targets for tumor vaccines [106]. This evidence concerns the gene TP53 and neoplasm.